...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement

KK2 - Your concept is correct. In practicality there could be some significant challenges. That type of deal now would fragment the company (RVX). Apabetalone would be most valuable sold to one company for all of its potential uses. CKD use could be as big or bigger that CVD use.

ASSURE/SUSTAIN and the Crestor results; It is my understanding that for plaque regression the Crestor/RVX-208 combo absolutely worked the best however for event cessation it was very close between both satins and RVX-208. Maybe having BEAR  or another science person chime in on this point would be good.

dyodd

tada

Share
New Message
Please login to post a reply